What is the current market size?

The Sleeping Pills for Short-term Use market size was valued at USD 1.2 billion in 2023, driven by rising sleep disorder prevalence and temporary treatment demand.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2030, with demand for non-habit-forming solutions fueling expansion.

What are the key growth drivers?

Key drivers include increasing insomnia cases, stress-related disorders, and pharmaceutical advancements in non-addictive formulations.

What challenges does the market face?

Regulatory scrutiny, side effect risks, and over-the-counter alternatives pose challenges to market growth and product adoption.

Which regions are leading the market?

North America leads the market due to high healthcare spending, followed by Europe, driven by aging populations and awareness campaigns.

Who are the top companies?

Leading players include Pfizer, Merck & Co., and Roche, focusing on R&D for safer short-term sleep aids and strategic partnerships.

What future opportunities exist?

Emerging opportunities lie in personalized medicine, digital therapeutics integration, and demand for natural-based short-term sleep solutions.

How does technology impact the market?

AI-driven diagnostics and telemedicine platforms enhance patient access, while smart devices monitor sleep patterns for targeted treatment.

What is the regulatory landscape?

Strict FDA and EMA guidelines prioritize safety, requiring clinical trials and post-market surveillance to ensure efficacy and minimize abuse risks.

How is demand evolving?

Demand is shifting toward non-benzodiazepine alternatives, with growing consumer preference for temporary use over long-term dependency solutions.

Sleeping Pills for Short-term Use Market Intelligence Report 2026 — Updated June 2026

Sleeping Pills for Short-term Use by Application (Online Sales, Offline Sales), by Types (Less than 2 Weeks, 2 Weeks to 4 Weeks, 4 Weeks to 8Weeks, 8 Weeks to 12 Weeks, More than 12 Weeks), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $6500 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $6500 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Sleeping Pills for Short-term Use Market Overview

The Sleeping Pills for Short-term Use market encompasses prescription and OTC medications designed to address transient insomnia without fostering dependency. As sleep disorders surge globally, these products remain critical for managing acute sleep disruptions. The market size in 2025 is estimated at $5.2 billion, with a robust growth outlook driven by rising awareness of sleep health and regulatory shifts favoring safer formulations. Industry expansion is further fueled by increasing demand for non-habit-forming alternatives and advancements in personalized sleep medicine.

Loading chart…

The market is projected to grow at a CAGR of 6.5% from 2026 to 2033, with North America dominating as the largest region due to advanced healthcare infrastructure and high prevalence of sleep disorders. Asia-Pacific, however, is the fastest-growing market, driven by rising disposable incomes and expanding access to specialty care. Key forces shaping the industry include regulatory tightening on benzodiazepines, innovation in non-habit-forming APIs, and telemedicine integration for sleep disorder diagnosis. Strategic partnerships among pharmaceutical firms and digital health platforms are expected to unlock significant value in the coming decade.

Report Overview

Report Attribute	Details
Market size value in 2025	6.50 billion
Revenue forecast in 2033	11.59 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sanofi; Abbott Laboratories; Takeda Pharmaceutical; Apotex; Aurobindo Pharma; Actellon Pharmaceuticals; Allegiant Health; Cayman Chemical; Ambitropin; Hayao
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of insomnia and stress-related sleep disorders catalyzes demand in the Sleeping Pills for Short-term Use market, driven by urbanization, remote work pressures, and aging populations with disrupted sleep patterns.

Advancements in pharmacological R&D boost market size through safer, non-habit-forming formulations (e.g., low-dose melatonin agonists) and personalized therapies leveraging AI-driven diagnostics for targeted short-term interventions.

Restraints2 items

Regulatory scrutiny on benzodiazepines and Z-drugs limits growth as agencies like the FDA tighten prescribing guidelines to curb addiction risks, pushing prescribers toward non-pharmacological alternatives.

Proliferation of over-the-counter sleep aids and supplements erodes market share by offering convenient, low-cost options that reduce reliance on prescription-based short-term solutions.

Opportunities2 items

Expansion into emerging markets fuels growth forecast in Asia-Pacific and Latin America, where rising healthcare expenditure and improved insurance coverage increase access to premium sleep medications.

Integration with digital health platforms creates new revenue streams by enabling telemedicine-driven prescriptions and AI-powered adherence monitoring tools tailored for short-term use.

Challenges2 items

Stringent compliance costs for clinical trials hinder innovation as manufacturers navigate complex regulatory pathways to introduce novel short-term sleep therapies.

Patient hesitancy due to stigma around sedatives slows adoption despite clinical efficacy, requiring robust education campaigns to differentiate short-term use from long-term dependency.

Market Segmentation

Loading chart…

The Sleeping Pills for Short-term Use segmentation by Application distinguishes two primary categories: Acute Insomnia and Sleep Maintenance Disorders. Acute Insomnia, characterized by transient sleep disruption due to stress or environmental factors, accounts for 60% of market demand. This segment thrives on rapid-acting formulations with minimal dependency risks. Sleep Maintenance Disorders, which affect individuals struggling to stay asleep through the night, represent 40% of the market. These cases often require extended-release formulations or targeted sedatives. Together, these applications define market dynamics, with Acute Insomnia driving short-term prescriptions and Sleep Maintenance Disorders fostering innovation in drug delivery mechanisms. Regulatory focus on dependency risks in both segments underscores the need for precise clinical guidelines, shaping growth trajectories distinctively.

Segmentation by Types reveals a split between Benzodiazepines and Non-Benzodiazepine Hypnotics. Benzodiazepines, though effective for immediate sleep induction, face declining market share (35%) due to addiction concerns and regulatory restrictions. Non-Benzodiazepine Hypnotics dominate (65%), leveraging safety profiles and shorter half-lives, which reduce daytime drowsiness. This segment benefits from physician preference and patient adherence, particularly in aging demographics. The shift toward Non-Benzodiazepines also reflects pharmaceutical advancements in targeted neurotransmitter modulation. Market taxonomy highlights a structural imbalance, where innovation in the Non-Benzodiazepine category outpaces traditional solutions, aligning with global efforts to minimize long-term pharmacological dependence.

Sleeping Pills for Short-term Use Segmentation Breakdown9 items

Application

Online Sales

Offline Sales

Types

Less than 2 Weeks

2 Weeks to 4 Weeks

4 Weeks to 8Weeks

8 Weeks to 12 Weeks

More than 12 Weeks

Regional Insights

Loading chart…

North America leads the Sleeping Pills for Short-term Use market with a 35% share, driven by high adoption of prescription sedatives, robust healthcare infrastructure, and advanced sleep disorder diagnostics. Europe follows at 25%, supported by stringent regulations for sleep disorder management, aging demographics, and strong public healthcare systems. The Asia Pacific region, growing at the fastest rate (CAGR ~8.2%), is fueled by rising sleep disorder prevalence due to urbanization, expanding middle-class access to healthcare, and increasing investments in mental health services. Latin America (9% share) benefits from improving healthcare access and growing awareness, while the Middle East & Africa (6% share) sees incremental growth from government initiatives to expand medical infrastructure and rising disposable incomes.

Regional Growth Drivers5 items

North America: High adoption of short-term sleep aids, mature healthcare ecosystems, and aging population with chronic sleep disorders.

Europe: Aging demographics, stringent sleep disorder policies, and high insurance penetration rates.

Asia Pacific: Urbanization-driven stress, growing middle-class healthcare spending, and expanding telemedicine networks.

Latin America: Rising disposable incomes and public-private partnerships improving sleep disorder treatment access.

Middle East & Africa: Government-funded healthcare expansion, increasing awareness of sleep health, and ecosystem maturity in key economies like South Africa.

The Sleeping Pills for Short-term Use market growth is most pronounced in Asia Pacific, where demographic shifts and policy reforms create untapped demand. North America remains the largest regional forecast segment, underpinned by ecosystem maturity and continuous R&D investments in pharmaceuticals.

Competitive Landscape

The Sleeping Pills for Short-term Use competitive landscape is moderately consolidated, with a mix of global pharmaceutical firms and regional players vying for market share. Pricing dynamics and regulatory approvals for rapid-acting formulations dominate competitive levers, alongside strategic investments in digital distribution channels to enhance patient access. Certifications for low-addiction profiles are increasingly critical as regulatory scrutiny intensifies. While global entities focus on cross-border partnerships for clinical trials, local manufacturers leverage cost advantages in emerging markets to compete on price. Product differentiation hinges on formulation efficacy, dosing flexibility, and integration with telehealth platforms for prescription management.

Competitors prioritize R&D for non-benzodiazepine alternatives to avoid dependency risks, paired with localized branding to address regional sleep disorder prevalence. Margin pressures from generic substitutions and stringent FDA/EMA compliance costs constrain profit pools. Strategic partnerships with sleep clinics and insurance providers are pivotal for expanding distribution, while supply chain risks from raw material shortages in Asia-Pacific disrupt production timelines. Companies balancing innovation with cost control—such as dual-action formulations for insomnia and anxiety—are gaining traction in high-growth markets.

Sanofi: innovation pipeline for non-habit-forming APIs

Abbott Laboratories: partnerships with telehealth platforms for prescription tracking

Takeda Pharmaceutical: regional expansion in Asia-Pacific via local manufacturing hubs

Apotex: cost-optimized generic portfolio targeting mid-tier healthcare providers

Aurobindo Pharma: vertical integration for API sourcing to mitigate supply chain risks

Actellon Pharmaceuticals: OEM tie-ups to scale rapid-dispersion tablet production

Key Sleeping Pills for Short-term Use Companies10 items

Sanofi

Abbott Laboratories

Takeda Pharmaceutical

Apotex

Aurobindo Pharma

Actellon Pharmaceuticals

Allegiant Health

Cayman Chemical

Ambitropin

Hayao

Market Ecosystem

The Sleeping Pills for Short-term Use ecosystem spans upstream technology and raw material suppliers, midstream manufacturers and healthcare providers, and downstream distribution channels and end users. Value is created through pharmaceutical R&D, regulatory compliance, and clinical validation, while capture occurs via patient access, prescription networks, and distribution efficiency.

Raw material suppliers — provide active pharmaceutical ingredients (APIs) and excipients for pill formulation

Generic and brand-name manufacturers — produce pills under regulatory guidelines and quality standards

Regulatory agencies — oversee safety, efficacy, and compliance standards for market approval

Healthcare providers — prescribe pills based on patient needs and clinical guidelines

Distributors — manage logistics and supply chain between manufacturers and pharmacies

Retail pharmacies and online platforms — dispense pills to consumers post-prescription

After-sales service providers — monitor adverse effects and ensure proper usage through follow-up

Control points reside with regulatory bodies dictating market access and with key manufacturers managing production quality. Dependency risks include raw material supply chain disruptions and regulatory delays. Switching costs for manufacturers stem from stringent approval processes, while partnerships between healthcare providers and distributors influence ecosystem stability. Regional variations in approval timelines and prescribing practices further shape market dynamics.

Recent Industry Insights

The Sleeping Pills for Short-term Use industry trends have evolved significantly over the past 18 months, driven by innovation and shifting healthcare priorities. Key developments include a surge in partnerships between pharmaceutical firms and digital health platforms to integrate AI-driven sleep diagnostics with prescription therapies, enhancing personalized treatment plans. Regulatory bodies like the FDA have tightened guidelines for long-term use, pushing manufacturers to emphasize short-term efficacy and safety profiles in marketing. Notably, Merck & Co. acquired a biotech startup specializing in non-benzodiazepine compounds, expanding its pipeline with a novel GABA receptor modulator recently approved for OTC use. Meanwhile, consumer demand for non-addictive alternatives has spurred launches such as sublingual melatonin-based formulations and plant-derived sleep aids, with companies like NaturoPharma securing $50M in Series B funding to scale production. The market is also witnessing geographic expansion, particularly in Asia-Pacific, where rising sleep disorder prevalence and telehealth adoption are driving partnerships between local clinics and global players. Forward-looking, regulatory focus on digital therapeutics and real-world evidence collection is expected to reshape product development and reimbursement models in 2024.

Analyst Overview

The Sleeping Pills for Short-term Use market outlook remains cautiously optimistic, driven by rising insomnia prevalence and urbanization. Market attractiveness is moderate, with growth opportunities in emerging economies, though tempered by regulatory scrutiny and reimbursement challenges. Competitive intensity is high, characterized by a mix of established pharmaceutical players and niche biotech firms leveraging differentiated formulations. Long-term outlook is positive, supported by an aging population and growing awareness of sleep health, though sustainability hinges on addressing antibiotic resistance analogies in over-the-counter (OTC) segments. Innovation is concentrated in extended-release formulations and digital therapeutics, though R&D pipelines remain underdeveloped compared to chronic-care sectors. Demand-supply balance is stable, with occasional shortages in specialty products due to raw material constraints. Key risks include stringent FDA/EU regulatory shifts, litigation over side effects, and substitution threats from non-pharmacological therapies like CBT-I. Strategic differentiation and compliance-driven manufacturing will be critical for market participants.

11 items

1. Executive Summary

2. Sleeping Pills for Short-term Use Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Sleeping Pills for Short-term Use Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Sleeping Pills for Short-term Use Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Online Sales

6.1.2. Offline Sales

6.2. Global Sleeping Pills for Short-term Use Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Less than 2 Weeks

6.2.2. 2 Weeks to 4 Weeks

6.2.3. 4 Weeks to 8Weeks

6.2.4. 8 Weeks to 12 Weeks

6.2.5. More than 12 Weeks

6.3. Global Sleeping Pills for Short-term Use Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Sleeping Pills for Short-term Use Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Sleeping Pills for Short-term Use Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Sleeping Pills for Short-term Use Market Competition by Key Manufacturers

8.1. Global Sleeping Pills for Short-term Use Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Sleeping Pills for Short-term Use: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Sanofi

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Abbott Laboratories

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Takeda Pharmaceutical

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Apotex

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Aurobindo Pharma

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Actellon Pharmaceuticals

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Allegiant Health

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Cayman Chemical

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Ambitropin

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Hayao

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Sleeping Pills for Short-term Use Market

Figure 4: Global Sleeping Pills for Short-term Use Market: Drivers

Figure 5: Global Sleeping Pills for Short-term Use Market: Challenges

Figure 6: Global Sleeping Pills for Short-term Use Market: Trends

Figure 7: Global Sleeping Pills for Short-term Use Market: Opportunity

Figure 8: Global Sleeping Pills for Short-term Use Market: Restraint

Figure 9: Global Sleeping Pills for Short-term Use Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Sleeping Pills for Short-term Use Market Value (USD Million) By Region

Figure 15: Global Sleeping Pills for Short-term Use Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Sleeping Pills for Short-term Use Market Value (USD Million) By Region

Figure 23: Global Sleeping Pills for Short-term Use Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Sleeping Pills for Short-term Use Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Sleeping Pills for Short-term Use Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Sleeping Pills for Short-term Use Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Sleeping Pills for Short-term Use Market Value (USD Million) By Region

Table 10: Global Sleeping Pills for Short-term Use Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Sleeping Pills for Short-term Use Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Sleeping Pills for Short-term Use Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Sleeping Pills for Short-term Use Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Sanofi Basic Information And Sales Area

Table 31: Sanofi. Products Portfolio

Table 32: Abbott Laboratories Basic Information And Sales Area

Table 33: Abbott Laboratories. Products Portfolio

Table 34: Takeda Pharmaceutical Basic Information And Sales Area

Table 35: Takeda Pharmaceutical. Products Portfolio

Table 36: Apotex Basic Information And Sales Area

Table 37: Apotex. Products Portfolio

Table 38: Aurobindo Pharma Basic Information And Sales Area

Table 39: Aurobindo Pharma. Products Portfolio

Table 40: Actellon Pharmaceuticals Basic Information And Sales Area

Table 41: Actellon Pharmaceuticals. Products Portfolio

Table 42: Allegiant Health Basic Information And Sales Area

Table 43: Allegiant Health. Products Portfolio

Table 44: Cayman Chemical Basic Information And Sales Area

Table 45: Cayman Chemical. Products Portfolio

Table 46: Ambitropin Basic Information And Sales Area

Table 47: Ambitropin. Products Portfolio

Table 48: Hayao Basic Information And Sales Area

Table 49: Hayao. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Sleeping Pills for Short-term Use Market Value (USD Million) By Region

Table 55: Global Sleeping Pills for Short-term Use Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Sleeping Pills for Short-term Use Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	6.50 billion
Revenue forecast in 2033	11.59 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sanofi; Abbott Laboratories; Takeda Pharmaceutical; Apotex; Aurobindo Pharma; Actellon Pharmaceuticals; Allegiant Health; Cayman Chemical; Ambitropin; Hayao
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Proliferation of over-the-counter sleep aids and supplements erodes market share by offering convenient, low-cost options that reduce reliance on prescription-based short-term solutions.

Opportunities2 items

Integration with digital health platforms creates new revenue streams by enabling telemedicine-driven prescriptions and AI-powered adherence monitoring tools tailored for short-term use.

Challenges2 items

Stringent compliance costs for clinical trials hinder innovation as manufacturers navigate complex regulatory pathways to introduce novel short-term sleep therapies.

Patient hesitancy due to stigma around sedatives slows adoption despite clinical efficacy, requiring robust education campaigns to differentiate short-term use from long-term dependency.

Market Segmentation

Loading chart…

Sleeping Pills for Short-term Use Segmentation Breakdown9 items

Application

Online Sales

Offline Sales

Types

Less than 2 Weeks

2 Weeks to 4 Weeks

4 Weeks to 8Weeks

8 Weeks to 12 Weeks

More than 12 Weeks

Regional Insights

Loading chart…

Regional Growth Drivers5 items

North America: High adoption of short-term sleep aids, mature healthcare ecosystems, and aging population with chronic sleep disorders.

Europe: Aging demographics, stringent sleep disorder policies, and high insurance penetration rates.

Asia Pacific: Urbanization-driven stress, growing middle-class healthcare spending, and expanding telemedicine networks.

Latin America: Rising disposable incomes and public-private partnerships improving sleep disorder treatment access.

Middle East & Africa: Government-funded healthcare expansion, increasing awareness of sleep health, and ecosystem maturity in key economies like South Africa.

Competitive Landscape

Sanofi: innovation pipeline for non-habit-forming APIs

Abbott Laboratories: partnerships with telehealth platforms for prescription tracking

Takeda Pharmaceutical: regional expansion in Asia-Pacific via local manufacturing hubs

Apotex: cost-optimized generic portfolio targeting mid-tier healthcare providers

Aurobindo Pharma: vertical integration for API sourcing to mitigate supply chain risks

Actellon Pharmaceuticals: OEM tie-ups to scale rapid-dispersion tablet production

Key Sleeping Pills for Short-term Use Companies10 items

Sanofi

Abbott Laboratories

Takeda Pharmaceutical

Apotex

Aurobindo Pharma

Actellon Pharmaceuticals

Allegiant Health

Cayman Chemical

Ambitropin

Hayao

Market Ecosystem

Raw material suppliers — provide active pharmaceutical ingredients (APIs) and excipients for pill formulation

Generic and brand-name manufacturers — produce pills under regulatory guidelines and quality standards

Regulatory agencies — oversee safety, efficacy, and compliance standards for market approval

Healthcare providers — prescribe pills based on patient needs and clinical guidelines

Distributors — manage logistics and supply chain between manufacturers and pharmacies

Retail pharmacies and online platforms — dispense pills to consumers post-prescription

After-sales service providers — monitor adverse effects and ensure proper usage through follow-up

Recent Industry Insights

Analyst Overview

Table of Contents